210 related articles for article (PubMed ID: 33302222)
1. NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.
Syed M; Mushtaq S; Loya A; Hassan U
Ann Diagn Pathol; 2021 Feb; 50():151660. PubMed ID: 33302222
[TBL] [Abstract][Full Text] [Related]
2. NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.
Yoshida KI; Machado I; Motoi T; Parafioriti A; Lacambra M; Ichikawa H; Kawai A; Antonescu CR; Yoshida A
Am J Surg Pathol; 2020 Jun; 44(6):719-728. PubMed ID: 31972596
[TBL] [Abstract][Full Text] [Related]
3. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors.
Wehrli BM; Huang W; De Crombrugghe B; Ayala AG; Czerniak B
Hum Pathol; 2003 Mar; 34(3):263-9. PubMed ID: 12673561
[TBL] [Abstract][Full Text] [Related]
4. Correlation NKX2.2 IHC and
Pasricha S; Pahwa S; Pruthi M; Jajodia A; Gupta G; Sharma A; Durga G; Kamboj M; Tiwari A; Panigrahi M; Mehta A
Indian J Pathol Microbiol; 2023; 66(1):58-62. PubMed ID: 36656211
[TBL] [Abstract][Full Text] [Related]
5. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
Lee AF; Hayes MM; Lebrun D; Espinosa I; Nielsen GP; Rosenberg AE; Lee CH
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):233-8. PubMed ID: 21084965
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Rushing EJ
Hum Pathol; 2010 May; 41(5):653-62. PubMed ID: 20138330
[TBL] [Abstract][Full Text] [Related]
7. NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25-case cohort study.
Chen W; Hornick JL; Fletcher CDM
Histopathology; 2021 Jan; 78(2):334-337. PubMed ID: 32779239
[TBL] [Abstract][Full Text] [Related]
8. [Expression and diagnostic value of NKX3.1 and NKX2.2 in mesenchymal chondrosarcoma].
Wang XX; Chen H; Wang X; Ma L; Cheng K; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):114-119. PubMed ID: 35152629
[No Abstract] [Full Text] [Related]
9. Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations.
Devaney K; Vinh TN; Sweet DE
Hum Pathol; 1993 Nov; 24(11):1211-25. PubMed ID: 7503935
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor.
Folpe AL; Hill CE; Parham DM; O'Shea PA; Weiss SW
Am J Surg Pathol; 2000 Dec; 24(12):1657-62. PubMed ID: 11117787
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma.
Hung YP; Fletcher CD; Hornick JL
Mod Pathol; 2016 Apr; 29(4):370-80. PubMed ID: 26847175
[TBL] [Abstract][Full Text] [Related]
12. The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma.
Shibuya R; Matsuyama A; Nakamoto M; Shiba E; Kasai T; Hisaoka M
Virchows Arch; 2014 Nov; 465(5):599-605. PubMed ID: 25031013
[TBL] [Abstract][Full Text] [Related]
13. NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population.
Ramanayake N; Vargas AC; Talbot J; Bonar F; Wong DD; Wong D; Mahar A; Karim R; Luk PP; Selinger C; Sioson L; Gill AJ; Maclean F
Pathology; 2021 Oct; 53(6):705-712. PubMed ID: 33640159
[TBL] [Abstract][Full Text] [Related]
14. Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Santi M; Judkins AR; Rushing EJ
Ann Diagn Pathol; 2010 Feb; 14(1):8-14. PubMed ID: 20123451
[TBL] [Abstract][Full Text] [Related]
15. NKX3.1 immunohistochemistry and methylome profiling in mesenchymal chondrosarcoma: additional diagnostic value for a well-defined disease?
Glauser S; Ameline B; Andrei V; Harder D; Pauli C; Trautmann M; Hartmann W; Baumhoer D
Pathology; 2023 Aug; 55(5):621-628. PubMed ID: 37225644
[TBL] [Abstract][Full Text] [Related]
16. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton.
Müller S; Söder S; Oliveira AM; Inwards CY; Aigner T
Mod Pathol; 2005 Aug; 18(8):1088-94. PubMed ID: 15731776
[TBL] [Abstract][Full Text] [Related]
17. Ewing sarcoma and Ewing-like tumors.
Sbaraglia M; Righi A; Gambarotti M; Dei Tos AP
Virchows Arch; 2020 Jan; 476(1):109-119. PubMed ID: 31802230
[TBL] [Abstract][Full Text] [Related]
18. CD99 reactivity in mesenchymal chondrosarcoma.
Granter SR; Renshaw AA; Fletcher CD; Bhan AK; Rosenberg AE
Hum Pathol; 1996 Dec; 27(12):1273-6. PubMed ID: 8958297
[TBL] [Abstract][Full Text] [Related]
19. NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma.
Yoshida A; Sekine S; Tsuta K; Fukayama M; Furuta K; Tsuda H
Am J Surg Pathol; 2012 Jul; 36(7):993-9. PubMed ID: 22446943
[TBL] [Abstract][Full Text] [Related]
20. Confirmation of NKX3-1 Expression in EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma Using Monoclonal Antibody Immunohistochemistry, RT-PCR, and RNA In Situ Hybridization.
Yoshida A; Hashimoto T; Ryo E; Yoshida KI; Motoi T; Yatabe Y; Mori T
Am J Surg Pathol; 2021 Apr; 45(4):578-582. PubMed ID: 33443863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
